Far East Drug to acquire a majority stake in RRJ Capital-backed Fullerton Health.

Far East Drug, a drug manufacturer, agreed to acquire a majority stake in RRJ Capital-backed Fullerton Health, an integrated enterprise healthcare service provider. Financial terms were not disclosed. “Far East Drug is a strong and like-minded strategic partner. This synergistic collaboration between our entities will propel us towards an even higher growth trajectory. We are excited to work together and further develop our value proposition across Asia. This partnership maximizes our ability to broaden the coverage of and deepen access to healthcare services across the region. As always, we remain steadfast in our commitment to delivering excellence to all our clients and patients. This alliance will allow us to raise the bar on the value we provide to all stakeholders," Ho Kuen Loon, Fullerton Health Group CEO and Executive Directorr.